Advert - GlaxoSmithKline UK Limited – Case AUTH/3515/5/21

Activities at a meeting and promotion of Seretide

For referring to three medicines (Trelegy (fluticasone/vilanterol/umeclidinium), Anoro (vilanterol/umeclidinium) and Incruse (umeclidinium)) licensed for chronic obstructive pulmonary disease (COPD) but not asthma on a registration page for an asthma-focussed webinar, within a list of medicines which were indicated for use in asthma, which implied that the medicines could be used in asthma when their summaries of product characteristics stated that they should not be used in patients with asthma and was a matter of patient safety, GlaxoSmithKline was ruled in breach of the following clauses of the 2019 Code:

Clause 2 - Bringing discredit upon, and reducing confidence in, the pharmaceutical industry
Clause 3.2 - Promotion inconsistent with the summary of product characteristics
Clause 9.1 - Failing to maintain high standards